Aspen Neuroscience (ASPE) stock

Stem cell therapies , market cap $342M

Stem cell therapies made from own cells

Worth $342M

$12.43

+0.24%

As of 10:26 AM ET, delayed 15+ min · Live for Pro members

Quality Score

New listing

Checks firing

2of 14

Transition

From its high

-16.6%

under its best since listing

ASPE's Quality Score rose 2 points on Mon, Nov 9, to 3. Its high and its low were both higher than the day before (2 chart checks started or joined).

Trading since Oct 30, 2026. 8 trading days so far, so 11 of the 14 chart checks wait for more history.

Follow ASPE's trial news. Pro members can get an alert when Aspen Neuroscience files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ASPE files news on its trialSee it live, free for 24 hours. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on ASPE

Key facts on ASPE
Latest filing	8-K, Nov 2 Changed its bylaws or fiscal year

ASPE in the news

Fri Nov 6Aspen continues refining employer partnership program for Lumberyard aspendailynews.com and 1 more ASPE closed +5.8% that day.

ASPE catalysts

Coming up

What's next for ASPE

Its trials

A trial underway: ASPIROPhase 1 · By invitation · 9 people · main data estimated Mar 30, 2027 · NCT06344026

For Pro members: 1 filing.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Peter A. Thompson bought 1,000,000 shares on Nov 2. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade.

Get an alert when ASPE files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why ASPE scores 3

New listingfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

+2Chart checks 2 of 14 firing right now, one point each
+1Insider trades Arch Venture Fund X, L.P. (10% owner) bought $1M on Nov 2, and 3 more filings

No effect today: Long-term trend, Run-up, Size, Profit, Growth, Dilution, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on ASPE and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:26 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when ASPE's Quality Score turns up

A free account. No card.

How ASPE ranks in Pharma

ASPE is a new listing, ranked from its 22nd trading day.

How ASPE ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	9/14	22
2	LLYEli Lilly	7/14	20
3	GMABGenmab	7/14	18
	ARVNArvinas		Open for its score
	ARWRArrowhead Research		Open for its score
	AZNAstraZeneca		Open for its score
	BMYBristol-⁠Myers Squibb		Open for its score
New	ASPEAspen Neuroscience	2/14	3

ASPE has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ASPE, and all 14 on every stock.Get in free →

The deep dive on ASPE

What it does and how it makes money1 findingFor Pro members1 finding on what ASPE does and how it makes money, for Pro members
Who holds and trades it1 findingInsiders bought $20.0M of shares on the open market in 90 days, with no sales; the largest, 10% owner Arch Venture Fund X, L.P., bought $18.0M on Nov 2, 2026.Form 4, filed Nov 2, 2026

ASPE share count over time

Offerings, shelves, and splits of ASPE, from its filings
From its filings	Filed
Raised $140.6M in a sale of shares, about 41% of its market value	Oct 30, 2026
Registered shares for sale (S-1)	Oct 9, 2026

ASPE insider trades

One insider bought $20M across 3 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyArch Venture Fund X, L.P.$18M10% ownerat $15.00 on Nov 2, filed Nov 2

BuyArch Venture Fund X, L.P.10% owner$18Mat $15.00 on Nov 2, filed Nov 2

All 3 insider filings on ASPE from the last six months, for Pro members.

All ASPE insider trades

ASPE's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Faheem HasnainExecutive Chair · no trades on file
Andrew SpaventaDirector · no trades on file

See insider trades by person

About Aspen Neuroscience

Aspen Neuroscience Inc is a clinical-stage, regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to initially address neurodegenerative diseases with high unmet medical need. The company's flagship program, sasineprocel, is an investigational autologous iPSC-based therapy for Parkinson's disease designed to replace a patient's lost dopamine neurons with dopaminergic neuron precursor cells.

aspenneuroscience.com

Listed on Nasdaq on Oct 30, 2026, and is 17% below its $15 offer price now. Its IPO filing and first days

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ASPE and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn ASPE's score around: 1 thing
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayNov 2Arch Venture Fund X, L.P. bought ASPE$18M at $15.00, filed Nov 2

Alerts are optional.

See ASPE's 14 chart checks

See it live, free for 24 hours. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: ASPE's Quality Score is 3 (New listing). Insiders bought $20M in the last 6 months (Form 4).

What does ASPE's Quality Score say?

ASPE scores 3 today, which Breakaway calls Below Average. It has 2 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ASPE's Quality Score?

ASPE scores 3 today, which Breakaway calls Below Average (0 to 5). The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ASPE's 3.

Are insiders buying ASPE?

One insider bought $20M across 3 filings in the last 6 months. No open-⁠market sales on record. The newest is Arch Venture Fund X, L.P., 10% owner, who bought $18M on Nov 2. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.